Furthermore, PD-1 inhibitor therapy in HCC frequently induces immune-related adverse events (irAEs), with an objective response rate (ORR) of 31% and grade 3/4 irAEs incidence of 37% observed in anti-PD-1/anti-CTLA-4 combination therapy for advanced HCC (8). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.